

References

- ***Abramson MJ, Puy RM and Weiner JM. (2003):*** Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003; (4): CD001186.
- ***Adkinson NF Jr, Eggleston PA, Eney D, et al .(1997):*** Bacon JR, Hamilton RG, Weiss ME, Arshad H, Meinert CL, et al. A controlled trial of Reference: immunotherapy for asthma in allergic children. N Engl Med 1997; 336 (5): 324-31.
- ***Akdis M and Akdis CA.(2007):*** Mechanisms of allergen of allergen-specific immunothera by. J Allergy Clin Immunol 2007; 119 (4): 780-9. Epub February 2007.
- ***Allman D, Srivastava B and Lindsley RC (February 2004).*** "Alternative routes to maturity: branch points and pathways for generating follicular and marginal zone B cells". Immunol. Rev. **197**: 147–60. doi:10.1111/j.0105-2896.2004.0108.x. PMID 14962193.
- ***American Academy of Allergy, Asthma and Immunology (2004):*** Patients & Consumers Center: Asthma & Allergy Medications. Available at: <http://www.aaaai.org>.
- ***American Lung Association (ALA) (2004):*** Asthma & Allergy: Childhood Asthma Overview; Available at: <http://www.lungusa.org/site>.

- ***American Lung Association, Epidemiology and Statistics Unit, Research and Program Services (May 2005):***Trends in asthma morbidity and mortality,. Available from www.lungusa.org/atf/cf/%7b7a8d42c2-fcca-4604-8ade-7f5d5e762256%7d/asthma1.pdf. Accessed August 4, 2006.
- ***Anderson S,and Daviskas E(2002):***the mechanism of exercise induced asthma .J Allergy Clin Immunol,106(3):453-9.
- ***Andrew H. Liu, Joseph D. Spahn and Donald Y.M. Leung (2004):*** Childhood asthma. Nelson text book of paediatrics 17th Edition 2,2004,134:760-774.
- ***Anolik J and Sanz I. (2004):*** B cells in human and murine systemic lupus erythematosus. Curr.Opin.Biol.Rheumatol., 16:505—512.
- ***Anupama, N, Vishnu H, sharma, M, et al . (2005):*** The serum immunoglobulin in level effects the severity of bronchial asthma volume 18 p 35-40 155 N 0857-5754.
- ***Asthma Prevalence, Health Care Use, and Mortality, (2000-2001):***, National Center for Health Statistics, Centers for Disease Control and Prevention. autoimmune disease. Arthritis Res Ther ;5 Suppl 4:S17-21.

- **Ball TM, Castro-Rodriguez JA, Griffith KA ,et al.(2003).** Siblings, day-care attendance, and the risk of asthma and wheezing during childhood .N Engl J Med 2003, 343:538-4.
- **Barnes P (2003):** Pathophysiology of asthma, EUR Respir Monograph, 23:84-113.
- **Bentley, A.M, Menz, G and Storz, C et al .(2004):** Identification of T-lymphocytes, macrophages and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am. Rev. Respir. Dis., 146 : 500 – 6.
- **Berlin , Wong GW, Hui DS, Chan HH, et al(2003).** Prevalence of respiratory and atopic disorders in Chinese schoolchildren. *Clinical Exp Allergy* ;31:1225–1231.
- **Bernstein IL, Bernstein DI and Dubb JW. (2004):** Faierman I, Wallin B. A Placebo- controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. *J Allergy Clin Immunol* 2004 (2): 317-24.
- **Bona C, Francisco A and Bonilla A (1995):** Textbook of Immunology. Martin Soohoo (2 ed.). CRC Press. p. 102.

- **Bona, Constantin, Francisco A and Bonilla (1996):**"5". Textbook of Immunology. Martin Soohoo (2 ed.). CRC Press. p. 102. ISBN 9783718605965.
- **Bonilla FA. B cell development. UpToDate.(2007):** <http://www.uptodate.com>. Accessed May 12, 2009.
- **Bousquet, J.; Vignola, A.M. Chanez and Campbell A.M.(2006):** Airways remodeling in asthma: no doubts,no more? Am J Respir Cell Mol Biol; 20, 777 – 786
- **Boyce JA. (2003):** Mast cells: beyond IgE. J Allergy, Clin Immunol : 111 (1): 2+ 32; quiz 33.
- **Bubien JK, Zhou Lj and Bell PD (1993) :**"Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca²⁺ conductance found constitutively in B lymphocytes.". J. Cell Biol. 121 (5): 1121–32. doi:10.1083/jcb.121.5.1121. PMID 7684739.
- **Busse W and Lemanske F (2001):** Jr. Asthma. N Engl J Med.2001; 344(5): 350 -362.
- **Busse WW. The role of leukotrienes in asthma and allergic rhinitis.(1996):** Clin Exp Allergy 1996; 26(8): 868- 79. Review. Expert panel. Report 3 . (2007): Guidelines for the diagnosis and management of asthma. National Institutes of Health, National Heart Lung and Blood Institutes. NIH publication NO. 91-4051.

- ***Cai J and Terasaki P (2005):*** Humoral theory of transplantation: Mechanism, prevention, and treatment. *J Hum Immunol.*, 66: 334- 342.
- ***Canodian GW and Passalacqua G.(2003):***Noninjection routes for immunotherapy. *J Allergy Clin Immunol* 2003; 111 (3): 437- 48, quiz 449
- ***Center for Disease Control and Prevention (CDC, 2006):*** National Center for Health Statistics . Health E-Stats: Asthma Prevalence, Health Care Use and Mortality, Available at: <http://www.cdc.gov>.
- ***Chen and Shi (2006) :*** Bronchial asthma pathophysiology, *Chest*; 123 (10030):4775-449.
- ***Chehab G, Sander O, Fischer-Betz R and Schneider M. (2007):***Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus. *Rheumatology.*,66(4):328, 330-6.
- ***Children's Allergy Clinic Jl Taman Bendungan Asahan 5 Jakarta Pusat, Jakarta Indonesia 10210 Phone.(2009) :*** (021) 70081995–5703646.
<http://www.childrenallergyclinic.wordpress.com/>
- ***Coon M (2009) :***Is the complement system irreducibly complex? The Tal Origins Archive. 2002.
<http://www.medscape.com/px/trk.svr/isitetargeting20?exturl=h>

<http://www.talkorigins.org/faqs/behe/icsic.html>. Accessed May 12, 2009.

- ***Cragg MS, Walshe CA, Ivanov AO and Glennie MJ (2005):*** The biology of CD20 and its potential as a target for mAb therapy. *Curr Dir Autoimmun.* 2005;8:140-174.
- ***Dagoye D, Zegaye B, and Kifle W (2003)*** :Wheezing, Allergy, and Parasite Infection in Children in Urban and Rural Ethiopia. *Am J Respir Crit care Med.* 2003; 167:1369-73.
- ***Deykin A, Massaro AF, Drazen JM and Israel E.(2002):*** Exhaled nitric oxide as a diagnostic test for asthma: online versus offline techniques and effect of flow rate. *Am J Respir Crit Care Med* 2002; 165(12): 1597-1901.
- ***Di Rienzo V, Marcucci F, Puccinelli P, et al.(2003):***Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. *Clin Exp Allergy* 2003; 33(2): 206-10.
- ***Djukanovic R (2002):*** Airway inflammation in asthma and its consequences: Implication for treatment in children and adults. *J Allergy Clin Immunol*:539-48.
- ***Dorner T and Radbruch B. (2005):*** B cells differentiation. *J.Exp.Med.*, (201)497-499.
- ***Drazen |Jeffery M(2000):*** Cecil Textbook of Medicine. 20 ed. Philadelphia, wB Saunders Company, pc.: 76-812000.

- ***Drazen J. M., Isreal E and Boushsy H. A. (2006):*** Comparison of regularly-scheduled with as-needed use of albuterol in mild asthma, Asthma Clinical Research Network. N. Eng. J. Med.. 335: 841-847.
- ***Duffy M, Jacobsen B and Bratmar L(2002):*** Statistical methods for health care research. 4th edition. University of Pennsylvania, Boston College Lipincott U.S.A. 2002:1-412.
- ***Eat dirt. The hygiene hypothesis and allergic diseases. N Engl J Med (2002):*** 347; 930-931.
- ***Eder W, Ege J and von Mutius E (2006) :***The asthma epidemic. N Engl J Med. 2006; 355(21): 2226-2235.
- ***Edwards J, Leandro M and Cambridge G (2004):*** B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. J.Rheum.Dis. Clin.North.Am., 30: 393-403.
- ***El-Bossaty W F (2010):*** The study of expression of CD20 versus CD27 positive b lymphocyte in rheumatoid arthritis. Master degree in Biochemistry. Under supervision of Mostafa MR,. Yousef AM. Aboueladab EA and Elshabacy FA , Faculty of Science, Mansoura University.
- ***El-Lawindi M, Mostafa N and Abu Haashima F (2003) :*** Bronchial Asthma among children: Disease Burden and Exacerbation Determinants. The Egyptian Journal of community Medicine ;21:51-76.

- ***El- Shafey AM .(2006):*** Study of the prevalence of bronchial asthma and other atopic diseases among school children in Cairo metropolitan ,Master degree in pediatrics. Under supervision of Deraz TE, EL Saify MY, and EL Gamal EM, Facultyof Medicine, Ain Shams University.
- ***Essawy.T.(2010) :***Anti-IgE Therapy in asthma ,Chest Department ,Benha University p:1-43.
- ***Expert and panel Report, (1997):*** Guidelines for the diagnosis and management of asthma. Publication No. 97-405. Bethesda MD, National Institutes at Healthy, National Heart, Lung, and blood institute.
- ***Eric, G. and Timothy, E. (2001):*** Bronchial asthma principles of diagnose and treatment. 4th ed. ME Gershuin and TE Albertson eds Human Press, Totowa NJ.
- ***Fang D, Nguyen TK and Leishear K (2005) :***"A tumorigenic subpopulation with stem cell properties in melanomas".
- ***Fausnight TB, Gentile DA and Skoner DP.(2005):*** Determining the cause of recurrent wheezing in infants. J Respir Dis Pediatricians. 2005;4:126-131.
- ***Ferreira MA (2010):*** Inflammation in allergic asthma: initiating events, immunological response and risk factors. Respirology 2004;9(1):16–24.

- ***Fish J and peter S , (2001).*** STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. *J Immunol*;161:5027–5038.
- ***Ford ES (2005):*** The epidemiology of obesity and asthma. *J Allergy Clin Immunol* 2005; 896- 909; quiz 910.
- ***Fuhlbrigge AL, Weiss ST, Kuntz KM and Paltiet AD.(2006):*** Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma. *Pediatrics* 2006; 118(2): e347-55. Dpub July 2006.
- ***Ganong WP. (2005):*** Gas transport between the lungs and the tissues. *Review of Medical Physiology*. 22nd ed. New York; McGraw-Hill; p. 666-9.
- ***Gelfand W and Dakhama A (2006):*** CD8+ T lymphocytes and leukotriene B4: novel interactions in the persistence and progression of asthma. *J Allergy Clin Immunol*. 2006; 117(3): 577-582.
- ***Gern E and Busse W. (2002):*** Relationship of viral infections to wheezing illnesses and asthma. *Nat Rev Immunol*. 2002; 2(2): 132-138.

- ***GINA 2002 Step 4 Treatment (2005)*** : INNOVATE. Allergy. 60; 309-316.
- ***Girish S, Scanlin T and Knop R (2005):*** Asthma www.emedicine.com .
- ***Global Initiative for Asthma (GINA 2005):*** Pocket guide for asthma management and prevention. Updated from global strategy for asthma management and prevention. No. 02-3659. Bethesda, MD: National Heart, Lung and Blood Institute, National Institutes of Health; 2005.
- ***Global Initiative for Asthma (GINA 2004):*** Global strategy for Asthma Management and Prevention (NHLBI/ WHO workshop report). National Institute of health publications 95:3659, 2.
- ***Global strategy for Asthma Management and Prevention (2002):*** National institute of health :National heart ,lung and Blood institute. Revised 2002. Available at:<http://www.ginasthma.com>
- ***Global strategy for Asthma Management and Prevention (2004):*** Bethesda (MD): Global Initiative for Asthma ,National Heart, Lung , and Blood Institute ;2004.
- ***Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA 2009):*** (online,2009).(updated December,2009).Available from: URL:<http://www.ginasthma.org>.

- ***Gorman C, Leandro M and Isenberg D(2003):*** B cell depletion in autoimmune disease. *Arthritis Res Ther* ;5 Suppl 4:S17-21.
- ***Green H, Brightling E and McKenna S (2002):*** Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. *Lancet*.2002; 360(9347): 1715-1721.
- ***Guilbert T and Krawiec M (2005):***Natural History of Asthma. In: David A. Stempel, Joseph spahn . *Pediatric clinics of North America*, volume 50, number 3, W.B . Saunders co 2005:7 – 24.
- ***Guyton C and Hall J. (2006):*** Effect of hemoglobin to 'Buffer' the tissue PO₂. *Text Book of Medical Physiology*. 11th ed. Philadelphia; Saunders; p. 507-8.
- ***Health and Medicine,(2008/9) Schools Wikipedia Selection.*** Related subjects;<http://en.wikipedia.org> .
- ***Hematol S (2001).*** Flow cytometry analysis of lymphomas and lymphoproliferative disorders.,*Apr*;38(2):111-23
- ***Holgate T, Casale T, Wenzel S, et al(2005):*** The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. *J Allergy Clin Immunol*.2005; 115(3): 459-465.
- ***Holgate ST and Finnerty JP (2002),***Novel mediators in chronic inflammation *Allergy Clin Immunol* 105:399–408

- ***Holgate ST and Polosa R (2006):*** The mechanisms, diagnosis, and management of severe asthma in adults. *Lancet*.2006; 368(9537): 780-793.
- ***Horvath I and Barnes J. (2002):***Exhaled monoxides in asymptomatic atopic subjects. *Clin Exp Allergy*. 2002; 29(9): 1276-1280
- ***Htrinex AA, Takabaysahi K and zubeldia JM(2005):*** Immunostimulatory DNA –based therapeutic for experimental and clinical allergy .*allergy* ; 57:24-29.
- ***Huss K, Adkinson NF, Eggleston PA et al.(2001):***House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program. *J Allergy Clin Immunol* 2001 Jan. 107 (1): 48-54.
- ***J Allergy Clin Immunol. 108: 2001; 184-190.*** Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
- ***Jacobi A and Diamond B (2005):*** Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus. *Curr. Biol.Rheumatol.*, 202 (3):341-344.
- ***Johnstone DE and Dutton A.(1968):*** The value of hyposensitization therapy for bronchial asthma in children, a 14-year study. *Pediatrics* 1968; 42(5): 793-802.

- ***K. John and Morrow Jr (2008):*** "Methods for Maximizing Antibody Yields". Genetic Engineering & Biotechnology News (Mary Ann Liebert, Inc.): p. 36.
http://www.genengnews.com/articles/ch_item.aspx?aid=2514.
Retrieved 2008-07-06.
- ***Kelley C, Mannino D, Homa D, et al. (2005):*** Asthma phenotypes, risk factors, and measures of severity in a national sample of US children. *Pediatrics*; 115; 726-773.
- ***Khattab, N. A.; El-Gazzar, A.G.; Eman, A. A. et al., (1997):*** Soluble IL-2 receptors and eosinophils in patients with bronchial asthma before and after salbutamol and anhydrous theophylline therapy. *Egypt J. Chest Dis. And Tuberculosis*, 44: 43-50.
- ***Khinchi MS, Poulsen LK, Carat F, et al , (2004):***Clinical efficacy of sublingual and subcutaneous birch pollen allergen-dummy study. *Allergy* 2004; 59(1): 45-53.
- ***Kljaic-Turkalj M, Cvoriscec B and Tudoric N (1996) :*** Decrease in CD23+ B lymphocytes and clinical outcome in asthmatic patients receiving specific rush immunotherapy. *Int Arch Allergy Immuno*, 111:188-94.
- ***Larche M (2003):*** anti –T cell strategies in the treatment of allergic disease.*allergy* 2003 ; 57(suppl 72):20 -33.

- **Lee SV, Kim SI, Moon HS, et al ,(2001)** :Distribution and cytokine production of lymphocyte subsets in patients with acute asthma attacks. *Ann Allergy Asthma Immun* 2001, 86:659-64.
- **Lemanske, R. and Busse, W. (2003);** Asthma. *J. Allergy Clin. Immunol.* 111(2): S 502- 519.
- **Levy Mark L, Monica Fletcher , David B. et al, (2006):** International Primary Care Respiratory Group (IPCRG) Guidelines: Diagnosis of respiratory diseases in primary care. *Primary Care Respiratory Journal* 2006; 15: 2034
- **Lin Z, Jian S, Jiannan F, et al , (2007):** BAFFtargeting therapy, a promising strategy for treating autoimmune diseases. *Pharmacology.* (597) 1:3-5.
- **Liu A,spahn J and leung D (2004):** childhood asthma .in :behran R ,kliegman RM , jenson H ,ed .nelson textbook of pediatrics ,17th ed. Philadelphia :WB Saunders ;p.760-774.
- **Mack ,C.L.,(2004)** : *pediatr. Res.*56:79.
- **Malo L, Lemiere C and Gautrin D (2004):** Occupational asthma. *Curr Opin Pulm Med.* 2004; 10(1): 57-61
- **Martinez F (2001):** factors for the development of asthma in: textbook of pediatric asthma ,naspitz C.et al (edit),1st edition , Martin L td .,London ,p.67-80.

- **Martinez FD ,stern DA and wright AL (2003):** Differential immune responses to acute lower ,respiratory illness in early life by subsequent development of persistent wheezing and asthma .J allergy clin immunol 2003;102 :915-20.
- **Maury S, Huguet F, Leguay T, et al . (2009):** Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Hematological; 95(2): 324–328.
- **Miles Weinberger. (2008):**Pediatric Asthma, Allergies and Diseases. Pediatr Health. 2008; 2(5): 631-650. Available at www.medscape.com
- **Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol (2001) :**108; S65-S71.
- **Moller C, Dreborg S, Ferdousi HA, et al , (2002):** pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT- study). J Allergy Clin Immunol 2002; 109(2): 251-6.
- **Murry M AND Pizzorno J (1995):**Encyclopedia of Natural Medicine .Little Brown &CO(UK)1995.
- **National Center For Health Statistics Asthma U.S(2002):** expert panel report :guidelines for the diagnosis and the management of asthma –update on selected topics 2002 J allergy clin immunol ; 110:S141-219

- **National Institute Of Health, National Heart, Lung and Blood institute (2008).** Asthma : who is at risk? sep 2008.
- ***National Heart, Lung, and Blood Institute. Accessed(November,2009):***<http://grants.nih.gov/grants/guide/pa-iles/PA-09-163>.
- ***National Institute of Environmental Health SciencesM (1997):***Fact Sheet #9 "ASTHMA and its Environmental Triggers: Scientists Take a Practical New Look at a Familiar Illness." July 1997.
- ***National Institute Of Health :National Heart ,Lung and Blood Institute. Revised (2002):*** Available at:[httpv.GINasthma.com](http://GINasthma.com).
- ***Nelson HS, Fernandez- and Caldas D.(2007):*** Prevalence of house dust mites in the Rocky Mountain states. *Ann Allergy Immunol* 2007; 75 (4): 337-9.
- ***NHLBI(National , Heart , Lung and Blood Institute (2007):***expert panel. guidelines for the diagnosis and management of asthma –update on selected topics, Bethesda ,MD:US department of health and human services . national heart ,lung ,and blood institute ; 2007 . NIH publications no.02-5075.

- **NHLBI/NAEPP EPR-3.** "Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. (EPR-3 Full report 2007)". NIH Publication No. 07-5051. Bethesda, MD: U.S. Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute; National Asthma Education and Prevention Program, August 2007.
- ***Olsen OT, Larsen KR and Jacobsan L.(1997):*** A 1-year, placebo-controlled, double-blind house-dust –mite immunotherapy study in asthmatic adults. *Allergy* 1997; 52(8): 853-9.
- ***Omalizumab, Anti-IgE Recombinant Humanized Monoclonal Antibody, (2001):*** For The Treatment Of Severe Allergic Asthma. *J Allergy Clin Immunol.* 108; 184-190.
- ***Pajno GB, Barberio G, De Luca F, et al .(2001):*** Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. *Clin Exp Allergy* 2001; 31(9): 1392-7
- ***Pescovitz M. (2005):*** Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action. *J.Am.Transplant.*6(5):859-866.

- **Petros P, Sfikakis A, John N, et al. (2005):** Rituximab Anti-B-Cell Therapy in Systemic Lupus Erythematosus: Pointing to the Future. *Curr.Biol.Rheumatol.*, 17(5):550-555.
- **Platts –Mills TA , Erwin E and Heymann P (2005):**is the hygiene hypothesis still a viable explanation for the increased prevalence of asthma ? allergy .2005;60suppl 79:25-31.
- **Poryadin GV, Zhurarleva NE and Kazamirson AN (2002):** Immunological mechanisms of recovery from an acute stage in patients with allergic bronchial asthma. *Russ J Immun*, 7:259-64.
- **Prajapati V and Mydlarski P. (2007):** Rituximab: A B-cell Depletion Therapy for Dermatologic Disease. *Arthritis.Res.Ther.*, 12(9):158-269.
- **Ramakrishnan K. and Borade A. (2010):** Anemia as a risk factor for childhood asthma. *Lung India*;27:51-53.
- **Rashad M.M., Mohammady E.A., Abd-Elaal I.A. and Sadek M.I. (2009):** Helicobacter pylori Infection and Childhood Bronchial Asthma; M.Sc. thesis; Faculty of Medicine, Benha University.
- **Attia R. (2003):** Exercise induced asthma and its prevalence in children aged (6-15). Master degree of pediatrics, pediatrics department , Ein shames university .

- ***Remes M and korpi M (2006):*** Asthma and atopy in school children in defined population .Act pediatric ,85:965-70.
- ***Sabahi R and Anolik J. (2006):*** B-cell-targeted therapy for systemic lupus erythematosus. Drug; 66(15):1933-48.
- ***Schools Wikipedia Selection (2008/9) :*** Related subjects: Health and medicine.
- ***Shereeder RL ,Castleman WL and kumar A (2003):*** prevention of chronic post – bronchiolitis airway sequelae with interferongamma treatment in rats .Am J respir crit care med 2003 ; 160:705 -10.
- ***Sly, R. M. (2000):*** Allergic disorders. In: Nelson, W. E.; Behrman, R.E.; Kliegman, R.M. and Arvin, A. M. (eds): Nelson, Textbook of Pediatrics. 17th ed. W. B. Saunders Company. Philadelphia.
- ***Stetler-Stevenson M. Flow cytometry analysis of lymphomas and lymphoproliferative disorders. Semin Hematol (2001):*** Apr;38(2):111-23.
- ***Stein R, Holberg J, Morgan J et al. (1997):*** Peak flow variability, methacholine responsiveness and atopy as markers for detecting different phenotypes in childhood. Thorax; 52: 946–952.
- ***Stewart C . U.S. (1997):***Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia

by flow cytometry: selection of antibody combinations. Cytometry (Communications in Clinical Cytometry) 30: 231-235 .

- ***Tedder, T.F.,(1994).*** CD20: a regulator of cell-cycle progression of Blymphocytes. Immunol. Today 15: 450-454
- ***Tedder TF , Streuli M, Schlossman SF et al (Mar 1988):***"Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes". Proc Natl Acad Sci U S A 85 (1): 208-12. PMID 2448768.
- ***The Anti-IgE Antibody Omalizumab Reduces Exacerbations And Steroid Requirement In Allergic Asthmatics. Eur Respir J (2001): 18;*** 254-26
- ***U.S. Environmental Protection Agency(2006) :***Asthma and indoor enviroments . About asthma . available at :<http://www.epa.gov/asthma-2004;25/6/2006>.
- ***Vignola, A.M.; Kips, J. and Bousquet J. (2004):*** Tissue remodeling afeature of persistant asthma .J. Allerg. Clin Immunol 105;1041-53
- ***Werb Z,Undergood J and Rappolee D (2002):***The role of macrophage derived growth factors in tissue repair.In:Mononuclear phaocytosis,Van Furth R.(edit),Kluwer Academic Press,p.404-9.

- **Walker, C.; Bode, E.; Boer, L. et al. (2001):** Allergic and non allergic asthmatics have distinct patterns of T cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. *Am. Rev. Resp. Dis.*, 146: 109- 15
- **WHO (2005):** Asthma, World Health Organization Website, <http://www.who.org>.
- **Wikipedia(2010):** Monocytes; <http://en.wikipedia.org/wiki/monocytes>.
- **Williams J. (2004) :** The eosinophil enigma. *J Clin Invest.* 2004; 113(4): 507-509.
- **Zeimpekoglou KY, MD, Ph. D (2008):** Pneumonologist, Department of Pneumonology, Hospital NIMITS PNEUMON Number 2, Vol. 21, April - June 2008
- **Zhu J. Qiu YS and Figueroa DJ (2005):** Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa. *Am J Respir Cell Mol Biol* 2005, 33:531-40. Epub.
- **Zimmerman B, D'Urzo A and Berube D (2004):** Efficacy and safety of formoterol Turbuhaler when added to inhaled corticosteroid treatment in children with asthma. *Pediatr Pulmonol.* 2004; 37(2):122-127.